CD274 and neoplasm: The PD-L1 tumor-targeting peptide sequence CVRARTR in this study is a functional peptide structure and a nanocarrier, which can target competitively block PD1/PD-L1 binding, revitalize effector-T-cell activity, and have antitumor immunotherapy effects [8–12].